- Report
- August 2022
- 120 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- August 2022
- 120 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- November 2023
- 163 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- December 2024
- 85 Pages
Spain
From €3340EUR$3,500USD£2,799GBP
- Report
- November 2023
- 190 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- November 2023
- 77 Pages
France
From €3340EUR$3,500USD£2,799GBP
- Report
- November 2023
- 178 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 178 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 175 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 190 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 190 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 138 Pages
North America
From €3818EUR$4,000USD£3,199GBP
- Report
- October 2023
- 122 Pages
North America
From €3818EUR$4,000USD£3,199GBP
- Report
- October 2023
- 181 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2021
- 131 Pages
Global
From €14311EUR$14,995USD£11,991GBP
- Report
- September 2021
- 126 Pages
Global
From €14311EUR$14,995USD£11,991GBP
- Report
- November 2023
- 164 Pages
Middle East, Africa
From €1432EUR$1,500USD£1,199GBP
- Report
- July 2023
- 147 Pages
Middle East, Africa
From €1432EUR$1,500USD£1,199GBP
- Report
- April 2023
- 326 Pages
Global
From €3436EUR$3,600USD£2,879GBP
- Report
- February 2022
- 185 Pages
Global
From €3436EUR$3,600USD£2,879GBP

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more